Treating class 2–3 obesity with glucagon‐like peptide‐1 agonists: A 2‐year real‐world cohort study

Documenti analoghi

• Characterisation of real‐world patients who discontinued a glucagon‐like peptide‐1 agonist
  di: Jessica Van Laren, et al.
  Pubblicazione: (2026)
• Trends in obesity and glucagon‐like peptide‐1 receptor agonist prescriptions in type 1 diabetes in the United States
  di: Yunwen Xu, et al.
  Pubblicazione: (2025)
• Long‐term safety and efficacy of glucagon‐like peptide‐1 receptor agonists in individuals with obesity and without type 2 diabetes: A global retrospective cohort study
  di: Yu‐Nan Huang, et al.
  Pubblicazione: (2024)
• Impact of glucagon‐like peptide‐1 receptor agonists on the incidence of inflammatory bowel disease in people with type 2 diabetes
  di: Fu‐Shun Yen, et al.
  Pubblicazione: (2025)
• Correction to “Long‐term safety and efficacy of glucagon‐like peptide‐1 receptor agonists in individuals with obesity and without type 2 diabetes: A global retrospective cohort study”
  Pubblicazione: (2025)